Sinco Pharmaceuticals Holdings Ltd - ESG Rating & Company Profile powered by AI
The ESG rating includes 17 United Nations Sustainable Development Goals including: 'Affordable & Clean Energy', 'Responsible Production & Consumption' and 'Life below Water'. Complete ESG analysis of Sinco Pharmaceuticals Holdings Ltd are reached by signing in. Scroll down to the bottom of the page for potential risks for Sinco Pharmaceuticals Holdings Ltd based on sector, geography and marketcap.
Sinco Pharmaceuticals Holdings Ltd in the Drug Retailers industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Sapporo Clinical Laboratory Inc | 8.0 | High |
2 | Nihon Chouzai Co Ltd | 7.5 | High |
... | ... | ... | |
68 | PharMerica Corp | 0.4 | Low |
68 | Rite Aid Corp | 0.4 | Low |
70 | Sinco Pharmaceuticals Holdings Ltd | 0.0 | Low |
70 | Cachet Pharmaceutical Co Ltd | 0.0 | Low |
70 | Camsing Healthcare Ltd | 0.0 | Low |
70 | Zhejiang Zhenyuan Share Co Ltd | 0.0 | Low |
70 | d1000 Varejo Farma Participacoes SA | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Sinco Pharmaceuticals Holdings Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Sinco Pharmaceuticals Holdings Ltd disclose current and historical energy intensity?
Does Sinco Pharmaceuticals Holdings Ltd report the average age of the workforce?
Does Sinco Pharmaceuticals Holdings Ltd reference operational or capital allocation in relation to climate change?
Does Sinco Pharmaceuticals Holdings Ltd disclose its ethnicity pay gap?
Does Sinco Pharmaceuticals Holdings Ltd disclose cybersecurity risks?
Does Sinco Pharmaceuticals Holdings Ltd offer flexible work?
Does Sinco Pharmaceuticals Holdings Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Sinco Pharmaceuticals Holdings Ltd disclose the number of employees in R&D functions?
Does Sinco Pharmaceuticals Holdings Ltd conduct supply chain audits?
Does Sinco Pharmaceuticals Holdings Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Sinco Pharmaceuticals Holdings Ltd conduct 360 degree staff reviews?
Does Sinco Pharmaceuticals Holdings Ltd disclose the individual responsible for D&I?
Does Sinco Pharmaceuticals Holdings Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Sinco Pharmaceuticals Holdings Ltd disclose current and / or historical scope 2 emissions?
Does Sinco Pharmaceuticals Holdings Ltd disclose water use targets?
Does Sinco Pharmaceuticals Holdings Ltd have careers partnerships with academic institutions?
Did Sinco Pharmaceuticals Holdings Ltd have a product recall in the last two years?
Does Sinco Pharmaceuticals Holdings Ltd disclose incidents of discrimination?
Does Sinco Pharmaceuticals Holdings Ltd allow for Work Councils/Collective Agreements to be formed?
Has Sinco Pharmaceuticals Holdings Ltd issued a profit warning in the past 24 months?
Does Sinco Pharmaceuticals Holdings Ltd disclose parental leave metrics?
Does Sinco Pharmaceuticals Holdings Ltd disclose climate scenario or pathway analysis?
Does Sinco Pharmaceuticals Holdings Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Sinco Pharmaceuticals Holdings Ltd disclose the pay ratio of women to men?
Does Sinco Pharmaceuticals Holdings Ltd support suppliers with sustainability related research and development?
Does Sinco Pharmaceuticals Holdings Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Sinco Pharmaceuticals Holdings Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Sinco Pharmaceuticals Holdings Ltd involved in embryonic stem cell research?
Does Sinco Pharmaceuticals Holdings Ltd disclose GHG and Air Emissions intensity?
Does Sinco Pharmaceuticals Holdings Ltd disclose its waste policy?
Does Sinco Pharmaceuticals Holdings Ltd report according to TCFD requirements?
Does Sinco Pharmaceuticals Holdings Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Sinco Pharmaceuticals Holdings Ltd disclose energy use targets?
Does Sinco Pharmaceuticals Holdings Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Sinco Pharmaceuticals Holdings Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Sinco Pharmaceuticals Holdings Ltd
These potential risks are based on the size, segment and geographies of the company.
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, including alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, the company engages in the purchase and sale of pharmaceutical products; and provides warehouse facilities for pharmaceutical products. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited is a subsidiary of Risun Investments Limited.